Nortriptyline 제제의 생물학적 동등성에 관한 연구

신재국,차인준,장인진,정원석,김용식,박찬웅,신상구 大韓臨床藥理學會 1993 臨床藥理學會誌 Vol.1 No.1

과량의 방사선에 노출된 흰쥐 소뇌외측핵의 미세구조

정재삼,양남길,안의태,고정식,박경호,김진국 대한해부학회 1992 Anatomy & Cell Biology Vol.25 No.3

만성 신부전 환자에서 혈액투석에 의한 Isoniazid의 제거

신재국,차인준,장인진,신상구,김윤구,한진석,김성권 大韓臨床藥理學會 1994 臨床藥理學會誌 Vol.2 No.2

Prednisolone과 Prednisone의 임상약동학적 평가

신재국,윤영란,차인준,이경훈,장인진,신상구,박찬웅 大韓臨床藥理學會 1994 臨床藥理學會誌 Vol.2 No.1

신경망 가변구조제어기 설계

박재삼,이진국 한국정보전략학회 1999 추계공동학술대회 논문집 Vol.- No.01

본 논문에서는 가변구조제어기의 슬라이딩모드이득과 경계층두께(boundary layer thickness)를 신경망을 이용하여 계산하는 신경망 가변구조제어기를 제시한다. 제시된 방법은 신경망의 역전파오차 학습기능을 이용하여 슬라이딩모드이득과 경계층 범위를 계산할 수 있도록 신경망 제어기를 학습시킴으로써, 슬라이딩모드 제어법칙을 단순화 하고, 시스템 불확실성에 대하여 강인하며, 추적오차를 더욱 개선시킬 수 있다. 설계의 예와 시뮬레이션 결과를 통하여 제시된 방법에 대한 유용성을 보인다.

임상시험의 개요

신재국,차인준 인제대학교 백병원 2002 仁濟醫學 Vol.23 No.1

Clinical trial has been extensively applied not only in drug development but for the academic researches in biomedical field. Since this is an experimental research in human subjects, the highest level of ethical and scientific requirements should be asked to the investigators and their processing. Therefore, it is not surprising that clinical trial in drug development is strictly controlled by the ethical committee (institutional review board, IRB) and governmental regulations. Good clinical practice (GCP) has been developed as a guideline to keep the ethical and scientific requirements of clinical trial. Unreliable data obtained from non-scientific approach can not be used for the bess application of drugs or medical devices in to patients, which is not ethical in terms of their unnecessary exposure in human subjects. The most ideal type of clinical trial includes prospective, randomized, controlled and double-blinded approach. This short review introduces some of the important concepts in clinical trial, especially in the design and preparation of protocol.

알루미늄과 헤테로폴리산으로 개질된 메조포러스 실리카 상에서의 AKD 합성

김현국,우창수,최재석,박민태,이병민,이호인 한국공업화학회 2003 응용화학 Vol.7 No.1

AKD(alkyl ketene dimer) used widely as a neutral sizing agent is produced industrially by halogenization of stearic acid followed by dimerization of alkyl ketene. In the present work, to suppress the byproduct of hydrochloric acid and to improve reaction pathway. AKD was prepared through of ketene intermediate by dehydration of stearic acid in gas phase using reaction with silanol on silica as active sites of the catalyst SBA-15 showed the highest activity due to the large and open tubular pores. It was found that main products were dimer and trimer. Our goal of the present work was to increase of the selectivity for the dimer.

植物凝集素 Dolichos lablab L.로 分類된 사람 血淸型에 관한 硏究

張訓梓,文國鎭 고려대학교 의과대학 1988 고려대 의대 잡지 Vol.25 No.1

Since the introduction of phytohemagglutinin (PHA) by Stillmark in 1898, PHA contributed to modicolegal field with new classification of blood types by their agglutination activities to human red blood cells and some of them have been used as lectins instead of antisera. Recently there were reported human serum types classified by their inhibition properties to agglutination reaction of panphytagglutinins with various red blood cells. To classify the serological relationships of human serum types classified by their agglutination activities to cat and rabbit red blood cells, and by their agglutination inhibition properties to D. lablab extract with cat and rabbit red blood cells, agglutination test and agglutination inhibition test with 1409 human sera were carried out. The results could be summarized as follows: 1. Human sera were classfied by their agglutination activities to cat red blood cells, and all rabbit red blood cells were agglutinated by human sera. 2. Human sera were also classified by their agglutination inhibition properties to D. lablab extract with cat and rabbit red blood cells and no serological relationship were demonstrated between them. 3. There were serological relationships between the human serum types classified by their agglutination activities and by their agglutination inhibition properties mentioned. 4. Human sera could be classified into 8 types by combination of their agglutination activities and by their agglutination inhibition properties to D. lablab extract with cat and rabbit red blood cells.

한국 무협소설의 존재 양상에 관한 고찰

김재국 한국현대문예비평학회 2003 한국문예비평연구 Vol.- No.13

Our chivalry novel have been recognized negatively in the literary world. But the chivalry novel is include a reader intention personality. Then we are contributing at the popularization of literature. The advantage of the chivalry novel is an entertainment facility. But an entertainment facility does not represent the chivalry novel. Because we can discover a lesson facility in the inside of such facility. The chivalry novel can give the proxy contentment of the desire to readers. And we are containing a resistive element about the inequality. We can say the chivalry novel is the literature to chanllenge at the sanctuary of literature. Let's look into some ways to make our chivalry novel activate. First of all we need the will of reader and writer in order to develop the chivalry novel. The publishing company must put the weight in the literary value than the commercial value. We must exert ourselves to an excavating, upbringing of a new figure in novel in long-time appreciation. The circulation structure of a lending store or a comic store must be improved. There is the possibility at the circulation of Internet cyberbookstore or a digital book form. We need the space which the writer talks with the reader continuously. The publishing company and the bookstore must effort together in this things. In order to do this things, the cyber space is most suitable. We must make the homepage for this first of all. We must do continuous update we do the link each other. The information exchange is possible through this. And it is sure to be activated for an appreciation, criticism, debate about the work. The chivalry novel will be shown new appearance with this task.

약물반응의 다양성과 약물유전학 : A Principle for the Personalized Pharmacotherapy

신재국,차인준 인제대학교 백병원 2002 仁濟醫學 Vol.23 No.2

Individual variation in drug response is a major problem of clinical practice and of a drug development. These variation can range from therapeutic failure to adverse or even fatal effects of drugs in some patients. The incidence of serious and fatal adverse drug reactions (ADRs) has been reported to be 6.7% and 0.32% of hospitalized patients in USA, respectively. The risk for therapeutic failure or toxicity of a drug in an individual patient is determined by the interaction of genes and environment. Environmental factors include drug-drug interactions, patient's age, weight, renal and liver dysfunction, or other disease factors or clinical variables such as smoking and alcohol consumption. Many of these environmental factors have long been considered in determining the individualized dose regimen in conventional pharmacotherapeutics. However, inherited individual variability of drug responses has been left as a so called "idiosyncrasy" that are not predictable by physicians. Recently, the rapid development of pharmacogenetics/pharmacogenomics provide us extensive informations regarding on the genetic background on the wide inter-individual variation of drug responses, which is expected to lead to the era of personalized pharmacotherapy. Pharmacogenetics is a science that is interesting to the inherited variants of genes related to pharmacokinetics (drug metabolizing enzymes, drug transporters etc.) and pharmacodynamics (receptor, ion channel, target enzyme etc.), which are associated to the susceptibility of an individual to the higher risk of ADR or therapeutic failure. This review addresses the role of pharmacogenetics/pharmacogenomics in relation to wide interindividual variation of drug responses and to the possible contribution to the prediction of personalized pharmacotherapy.